Inventia Life Science is advancing 3D bioprinting technology to revolutionise biomedical research and regenerative medicine.
Their strong foundation of fundamental research has led to the development of a proprietary platform encompassing bioprinting technology, an expanding library of printable bioink materials and custom protocols for specific applications.
The RASTRUM platform is now available to enable efficient and powerful bioprinting of 3D cell-based assays for biomedical research.
Advice from Blackbird founders and our team on what makes a strong investor to founder relationship, and how it evolves with time.
Meet Dr Julio Ribeiro, the co-founder and CEO of Inventia Life Sciences